XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $613K invested in XTL Biopharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
16% less capital invested
Capital invested by funds: $728K → $613K (-$114K)
20% less funds holding
Funds holding: 5 → 4 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$14.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19.5K |
| 2 |
Morgan Stanley
New York
|
-$15.4K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$843 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $483K | – | – | – |
|
|
2
Morgan Stanley
New York
| $80.6K | -$15.4K | -1,505 | -15% |
|
|
3
Citadel Advisors
Miami,
Florida
| $36.6K | +$4.62K | +451 | +13% |
|
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $13.2K | +$14.3K | +1,396 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$19.5K | -1,739 | Closed |
|
|
6
BNP Paribas Financial Markets
Paris,
France
| – | -$843 | -75 | Closed |
|
XTLB Hedge Fund Activity: Q2 2024 in Review
4 of the 6,930 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2024, worth a combined $613K — down 16% from $728K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XTLB and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $14.3K. The largest seller was UBS Group, exiting entirely with an estimated $19.5K sold.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2024, down from 5 in Q1 2024.
- Funds reported $613K of XTL Biopharmaceuticals stock for Q2 2024, down 16% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q2 2024 and 2 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals buyer in Q2 2024 was RhumbLine Advisers, an estimated $14.3K added.
- The largest XTL Biopharmaceuticals seller in Q2 2024 was UBS Group, an estimated $19.5K sold.
Based on aggregated 13F filings for Q2 2024.